Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Loretta J. Nastoupil"'
Autor:
Sattva S. Neelapu, Maria Alma Rodriguez, Jason R. Westin, Hubert H. Chuang, Ranjit Nair, Luis Fayad, Raphael E Steiner, Fredrick B. Hagemeister, Hua Jay J. Cherng, Homer A. Macapinlac, Christopher R. Flowers, Loretta J. Nastoupil, Paolo Strati, Hun Ju Lee, Lei Feng, Felipe Samaniego
Publikováno v:
Leuk Lymphoma
Many patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will not respond to platinum-containing salvage chemotherapy. Predicting treatment failure earlier could help clinicians minimize chemotherapy toxicities for non-responde
Autor:
Alexander, Augustyn, L Jeffrey, Medeiros, Ethan B, Ludmir, Jillian, Gunther, Penny, Fang, Shaoying, Li, Chi Young, Ok, Mikaela E, Bankston, Vivek, Verma, Dario, Pasalic, Sairah, Ahmed, Loretta J, Nastoupil, Jason R, Westin, Paolo, Strati, Sattva S, Neelapu, Ranjit, Nair, Raphael E, Steiner, Swaminathan P, Iyer, Alma, Rodriguez, Luis E, Fayad, Christopher R, Flowers, Bouthaina S, Dabaja, Chelsea C, Pinnix
Publikováno v:
Leuk Lymphoma
We addressed the prognostic impact of cell-of-origin (COO), MYC and Bcl-2 overexpression as well as isolated MYC rearrangement among 111 patients with limited stage diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiation therapy (R
Autor:
Collin K, Chin, Maria A, Rodriguez, Yun, Qing, Lei, Feng, Felipe, Samaniego, Preetesh, Jain, Mansoor, Noorani, Nathan H, Fowler, Luis E, Fayad, Jason R, Westin, Sattva S, Neelapu, Frederick B, Hagemeister, Christopher R, Flowers, Loretta J, Nastoupil
Publikováno v:
Leukemialymphoma. 61(12)
Autor:
Paolo, Strati, Mohamed Amin, Ahmed, Loretta J, Nastoupil, Lei, Feng, Fredrick B, Hagemeister, Luis E, Fayad, Maria A, Rodriguez, Felipe, Samaniego, Michael, Wang, Jason R, Westin, Hun J, Lee, Swaminathan P, Iyer, Simrit, Parmar, Sairah, Ahmed, Ranjit, Nair, Raphael E, Steiner, Mansoor, Noorani, Christopher R, Flowers, R Eric, Davis, Nathan H, Fowler, Sattva S, Neelapu
Publikováno v:
Leukemialymphoma. 61(6)
In 2 randomized phase 3 trials BR resulted in longer progression-free survival (PFS) than frontline R-CHOP in patients with indolent and mantle cell lymphoma. However, in subset analyses of follicular lymphoma (FL), the results were incongruent. We c
Autor:
Nathan Fowler, Sweet Ping Ng, Bouthaina S. Dabaja, Jillian R. Gunther, Sarah A. Milgrom, Zeina Ayoub, T.Y. Andraos, Chelsea C. Pinnix, Felipe Samaniego, Luis Fayad, Sattva S. Neelapu, Loretta J. Nastoupil
Publikováno v:
Leukemialymphoma. 60(13)
Patients with early-stage nodal follicular lymphoma (FL) may be rendered free of detectable disease by a diagnostic excisional biopsy. We reviewed the management and outcomes of 48 patients with FL, diagnosed from 2003-2013, treated at a single insti
Autor:
Francesco Turturro, Maria Alma Rodriguez, Anas Younes, Sattva S. Neelapu, Lei Feng, Loretta J. Nastoupil, Yago Nieto, Michelle A. Fanale, Fredrick B. Hagemeister, Yasuhiro Oki, Luis Fayad, Bei Hu, Jorge E. Romaguera, Amanda Copeland, Felipe Samaniego, Linda Claret, Jason R. Westin, Nathan Fowler
Publikováno v:
Leukemialymphoma. 59(4)
This phase-I/phase-II study evaluated panobinostat in combination with ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory classical Hodgkin lymphoma. During phase I, panobinostat was given daily on Monday/Wednesday/Friday starting one
Autor:
Michelle Byrtek, Jonathan W. Friedberg, Keith L Dawson, Rajni Sinha, Ryan Ziemiecki, Jean L. Koff, James R. Cerhan, Michael Taylor, Loretta J. Nastoupil, Brian K. Link, Christopher R. Flowers
Publikováno v:
Leukemialymphoma. 56(5)
To compare the effectiveness of frontline rituximab-chemotherapy regimens in clinical practice, we examined outcomes for patients with low-grade, stage III/IV follicular lymphoma receiving rituximab (R) with cyclophosphamide, doxorubicin, vincristine